


<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 05-403	<b>Serial No.</b> 10/536,939
 <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		<b>Applicant:</b> Christophe Revirron <b>Filing Date:</b> May 27, 2005 <b>Group:</b> TBD	

## U.S. PATENT DOCUMENTS




Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
VR	1.	WO 94/06429	31 March 1994	WO	31	495	✓	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

VR	2.	Bousquet, et al., "The management of allergic rhinitis symptoms in the pharmacy", Aria in the Pharmacy, Allergic Rhinitis and it's Impact on Astmas, pp. 1-25 FINAL DRAFT.
I	3.	Storms, William W., "Rethinking our approach to allergic rhinitis management", Ingentaconnect, Annals of Allergy, Asthma and Immunology, Vol. 88, Supplement 1, April 2002, Abstract.
I	4.	Gensthaler et al., "R-Enantiomer gegen Allergien" Levocetirizin XP-001147797 pp. 35-36.
I	5.	Juniper, Elisabeth F., "Measuring Health-Related Quality of Life in Rhinitis", J Allergy Clin Immunol, February 1997.
VR	6.	Juniper, Elisabeth F. and Guyatt, G.H., "Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis", Clinical and Experimental Allergy, Vol. 21, pp. 77-83, submitted 6 June 1990; revised 13 August 1990; accepted 13 August 1990.

7.	Gandon, J.M and Allain, H., "Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers". 2002 Blackwell Science Ltd Br J. Clin Pharmacol, 54, 51-58.				
8.	Grant et al., "A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and flare response during 24 hours in healthy male subjects, Annals of Allergy, Asthma & Immunology. pp. 190-197.				
9.	Mees et al., "Efficacy and safety of levocetirizine in seasonal allergic rhinitis", PubMed, Acta Otorhinolaryngol Belg. 2001;55(4):305-12.				
10.	Doctor's Guide, "Xyzal (Levocetirizine) Launched in England for Allergic Rhinitis", <a href="http://www.pslgroup/dg/207766.htm">http://www.pslgroup/dg/207766.htm</a> , October 1, 2001.				
11.	Doctor's Guide, "Germany Approves Antihistamines Xyzal and Xusal (Levocetirizine)", <a href="http://www.pslgroup.com/dg/1EFC66.htm">http://www.pslgroup.com/dg/1EFC66.htm</a> , January 16, 2001.				
12.	Salumun, et al., "Antihistamines in late-phase clinical development for allergic disease", Expert Opinion, Investigation Drugs (2002) 11(2):259-273.				
<table border="1"> <tr> <td>EXAMINER</td> <td>DATE CONSIDERED</td> </tr> <tr> <td></td> <td>1/3/2007</td> </tr> </table>		EXAMINER	DATE CONSIDERED		1/3/2007
EXAMINER	DATE CONSIDERED				
	1/3/2007				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 05-403	<b>Serial No.</b> To Be Assigned
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		10/536939	
		<b>Applicant:</b> Christophe Revirron	
		<b>Filing Date:</b> Herewith	<b>Group:</b> To Be Assigned

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
------------------	-----------------	------	------	-------	----------	----------------------------

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
W	A1	WO 94/06429 A	March 31, 1994	PCT		x

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

W	A2	XP002240083, "Xyzal (Levocetirizine) launched in England for Allergic Rhinitis", 2001, <a href="http://www.pslgroup.com/dg/207766.htm">www.pslgroup.com/dg/207766.htm</a> .				
	A3	XP002240084, "Germany Approves Antihistamines Xyzal", 2001, <a href="http://www.pslgroup.com/dg/lefc66.htm">www.pslgroup.com/dg/lefc66.htm</a> .				
	A4	Gensthaler, B. M., "Levocetirizine: R-enantiomer against allergies", <i>Pharmazeutische Zeitung</i> , 2001, Vol. 146, No. 7, pp. 35-36.				
	A5	Grant et al., "A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.", <i>Annals of Allergy, Asthma &amp; Immunology: Official Publication of the American College of Allergy, Asthma, &amp; Immunology</i> , 2002, Vol. 88, No. 2, pp. 190-197.				
W	A6	Gandon et al., "Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers.", <i>British Journal of Clinical Pharmacology</i> , 2002, Vol. 54, No. 1, pp. 51-58.				
EXAMINER <i>Christophe Revirron</i>			DATE CONSIDERED Jan 3/2007			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.